The Latest Breaking News on Pharma

Moderna's COVID vaccine lawsuit looks beyond the pandemic to future markets

Company says India is part of global transition to cornstarch-based powder

The COVID-19 vaccine is getting an upgrade.

Germany's Bayer said on Sunday it was starting a Phase III study program to investigate the efficacy and safety of asundexian, an oral Factor XIa (FXIa) inhibitor.

The chief executive officer believes most of the vaccinated population now has a "foundation immunity against severe disease"

NORFOLK, Va. — New data on fatal drug overdoses in Virginia suggests this year could be the first time there’s been a decrease in deaths since 2018.

Chief executive officer Pascal Soriot said he believes most of the vaccinated population has a ‘foundation immunity against severe disease’.

Indian authorities are probing allegations that a drug company bribed doctors to promote its anti-fever pills – the latest controversy involving the country’s pharmaceuticals industry.

The U.S. Food and Drug Administration (FDA) has approved Incyte’s (NASDAQ:INCY) Pemazyre (pemigatinib), a selective fibroblast growth factor receptor (FGFR) inhibitor, for the treatment of adults with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with FGFR1 rearrangement. Incyte shares traded in a range of $71.38 to $72.98 on day volume of 1.25…

Moderna sued Pfizer and its German partner BioNTech on Friday for patent infringement in the development of the first COVID-19 vaccine approved in the United States, alleging they copied technology that Moderna developed years before the pandemic. Pfizer shares fell nearly 1%, while BioNTech US-listed shares were down about 1.5%…

Hearing aid maker Eargo (EAR) reported disappointing second-quarter results. And analysts seem bearish about the company’s growth prospects. However, EAR climbed considerably following the FDA approval for over-the-counter hearing aid sales. After gaining nearly 198% over the past month, is EAR still a buy now? Read more to find out….